Chime Biologics
Wuhan, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A global CDMO providing end-to-end biologics manufacturing services with modular facilities and international regulatory expertise.
OncologyImmunologyInfectious Disease
Technology Platform
Modular, single-use bioprocessing facilities (KUBio) for flexible and scalable GMP manufacturing of diverse biologic modalities.
Opportunities
Growth is driven by increasing global outsourcing of biologics manufacturing, demand for cost-effective production, and the expansion of complex modalities like bispecific antibodies and cell therapies where they have developing expertise.
Risk Factors
Key risks include geopolitical tensions affecting cross-border operations, intense competition from established global CDMOs, and the perpetual challenge of maintaining consistent quality and regulatory compliance across multiple international sites.
Competitive Landscape
Competes with global CDMOs like Lonza, Samsung Biologics, and WuXi Biologics, differentiating through its integrated China-Europe model, emphasis on modular single-use facilities, and focus on client partnership and IP protection.